A 78-year-old male with a known history of exudative age-related macular degeneration in both eyes had been treated with intravitreal aflibercept injections for many years unable to extend past 5 weeks. He was recently treated in the right eye with intravitreal brolucizumab injection with resolution of his long standing intra-retinal fluid. After his third intravitreal brolucizumab injection in the right eye, the patient developed an episode of intraocular inflammation including anterior uveitis and vitritis. After being treated with topical difluprednate for one week, intraocular inflammation resolved. However, there have been reports of brolucizumab being associated with intraocular inflammation and occlusive retinal vasculitis. This aim of this presentation is to review the efficacy and adverse events related to brolucizumab.
Presentation Date: 04/30/2020
Issue Date: 08/01/2020